Fresh Hopes For Treatment Of Malaria In Africa (p 1218)October 10, 2001Despite the large number of deaths caused worldwide by AIDS, tuberculosis, and diarrhoeal diseases such as cholera, the biggest infectious-disease killer is still malaria, especially in Africa. Efforts to eradicate the carrier of malaria, a mosquito, have been only partly successful. The standard treatment for malaria has, for many years, been chloroquine, a fairly safe, effective, and cheap drug. Over the 40 years, from the 1940s to 80s, malaria parasites in Africa were highly sensitive to chloroquine. The first case of chloroquine resistance was reported in 1982. In Tanzania, Malawi, South Africa, and Kenya, front-line treatment has been, or is being changed to, a combination of antimalarial drugs - pyrimethamine-sulfadoxine. Over the past 10 years, there have been many reports that malaria parasites in these countries have become resistant to pyrimethamine-sulfadoxine. An alternative treatment is needed. The difficulties that researchers face in finding an alternative include finding a drug manufacturer willing to provide effective treatments at a price affordable to countries whose funds for purchasing drugs is severely limited: there is no point in effectively testing a "wonder drug" that no one can pay for. Dr Theonest Mutabingwa and colleagues from the National Institute for Medical Research in Tanzania tested two antimalarial drugs in a study in northeastern Tanzania, at Muheza, among 360 children less than five years old with falciparum malaria (the most severe form of the disease). The children were first given standard pyrimethamine-sulfadoxine treatment, and if their blood did not clear of parasites within seven days and they later developed a second episode of malaria they were given either a repeat dose of the same treatment or a new combination, chlorproguanil-dapsone. Repeat treatment with pyrimethamine-sulfadoxine resulted in only 39% of children being rid of malaria, whereas 93% of those treated with the new treatment (chlorproguanil-dapsone) were cleared of parasites. The urgency of Mutabingwa and colleagues' research is underlined by their comments that, "work on a combination of chlorproguanil-dapsone with artesumate is at an early stage of development. Drug development to international regulatory standards takes time, but Africa is in desperate need of an effective and affordable alternative to pyrimethamine-sulfadoxine." Lancet |
|||||||||||||||||||||
| Related Malaria Current Events and Malaria News Articles Measuring and modeling blood flow in malaria When people have malaria, they are infected with Plasmodium parasites, which enter the body from the saliva of a mosquito, infect cells in the liver, and then spread to red blood cells. On the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites. Research calls for better assessment of tests for tuberculosis, HIV/AIDS and malaria A rapid and accurate diagnosis is the first step towards treatment in the fight against infectious disease. Small nanoparticles bring big improvement to medical imaging If you're watching the complex processes in a living cell, it is easy to miss something important-especially if you are watching changes that take a long time to unfold and require high-spatial-resolution imaging. Prioritizing low-cost, simple health measures would save 2.5 million child lives a year Almost a third of the children under age five who die each year could be saved if governments rebalance health spending to ensure low-cost, simple interventions such as safe water and hygiene, bed nets and basic maternal and newborn care, leading aid agency World Vision said today. Currently, 8.8 million children a year die before age five, most of preventable causes. Drug industry, nonprofits join forces to fight world's neglected diseases Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. DNA barcodes: Creative new uses span health, fraud, smuggling, history, more The scientific ability to quickly and accurately identify species through DNA "barcoding" is being embraced and applied by a growing legion of global authorities - from medical and agricultural researchers to police and customs authorities to palaeontologists and others. PATH Malaria Vaccine Initiative shares strategy for developing 'next-generation' malaria vaccines Marking its tenth anniversary year, the PATH Malaria Vaccine Initiative (MVI) today unveiled a new strategy that sets the stage for an aggressive push targeting the long-term goal of eliminating and eradicating malaria. Malaria is one of the world's deadliest infectious diseases, killing nearly 900,000 people a year, most of them children in sub-Saharan Africa. More Malaria Current Events and Malaria News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||